|
2. Etiologie
|
|
|
|
3.1 Tabac
|
|
|
|
3.2 Prévention - Obésité
|
|
|
|
|
|
3.3 Prévention - Vaccins
|
|
|
France most skeptical country about vaccine safety [Science]
|
|
|
|
|
|
“I
didn’t expect France to be as negative as it was,” says Larson, who
runs The Vaccine Confidence Project, a nonprofit that monitors public
concerns about immunization. At the other end of the scale, only 0.2% of
the respondents in Bangladesh had similar safety misgivings.
|
|
|
|
|
|
|
|
4. Dépistage, diagnostic et pronostic
|
|
|
|
5.12.1 Immunothérapies - partenariats
|
|
|
|
5.12.2 Immunothérapies - CAR-T
|
|
|
|
|
|
5.2 Pharma
|
|
|
|
5.4 Traitements - Economie
|
|
|
|
5.5 ASCO
|
|
|
|
6. Lutte contre les cancers
|
|
|
|
NHS England sets out its vision for personalised medicine [PHG Foundation]
|
|
|
|
|
|
The
report is a welcome indication that NHS England has made the
development of personalised medicine a clear priority. This is an
important first step. It does not outline any new commitments but
provides a useful overview for the public of NHS England’s current
personalised medicine-related activities, including the 100,000 Genomes
Project and the 13 Genomic Medicine Centres (GMCs).
|
|
|
|
|
|
|
6.10.1 Politiques (USA)
|
|
|
|
|
6.6 Publications
|
|
|
|
|
How Much Does Publishing Cost? [The Scholarly Kitchen]
|
|
|
|
|
|
In
my view, we don’t have to decide which method is better: viewing
publishing as simply a production process or viewing it as a matter of
careful selection, whose success is measured by marketplace demand. Over
time these two processes will either eliminate the other or each find
its own place.
|
|
|
|
|
|